Article Type
Changed
Thu, 01/12/2023 - 10:47
Display Headline
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL

MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.

Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Meeting/Event
Publications
Topics
Legacy Keywords
Dr. Andrew W. Roberts, response rates, Bcl-2 inhibitor, ABT-199, chronic lymphocytic leukemia, CLL
Sections
Meeting/Event
Meeting/Event

MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.

Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.

Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Publications
Publications
Topics
Article Type
Display Headline
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL
Display Headline
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL
Legacy Keywords
Dr. Andrew W. Roberts, response rates, Bcl-2 inhibitor, ABT-199, chronic lymphocytic leukemia, CLL
Legacy Keywords
Dr. Andrew W. Roberts, response rates, Bcl-2 inhibitor, ABT-199, chronic lymphocytic leukemia, CLL
Sections
Article Source

AT THE EHA CONGRESS

PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.